UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 238

Sortiert nach

Avacopan for the Treatment of ANCA-Associated Vasculitis

The New England journal of medicine, 2021-02, Vol.384 (7), p.599-609

2021

Volltextzugriff (PDF)

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

Proceedings of the National Academy of Sciences - PNAS, 2020-01, Vol.117 (2), p.1129-1138

2020

Volltextzugriff (PDF)

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Journal of the American Society of Nephrology, 2017-09, Vol.28 (9), p.2756-2767

2017

Volltextzugriff (PDF)

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

PloS one, 2016-10, Vol.11 (10), p.e0164646-e0164646

2016

Volltextzugriff (PDF)

Cancer associated fibroblast FAK regulates malignant cell metabolism

Nature communications, 2020-03, Vol.11 (1), p.1290-1290, Article 1290

2020

Volltextzugriff (PDF)

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Journal of the American Society of Nephrology, 2014-02, Vol.25 (2), p.225-231

2014

Volltextzugriff (PDF)

Structural basis of ligand interaction with atypical chemokine receptor 3

Nature communications, 2017-01, Vol.8 (1), p.14135-14, Article 14135

2017

Volltextzugriff (PDF)

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

The lancet. Diabetes & endocrinology, 2015-09, Vol.3 (9), p.687-696

2015

Volltextzugriff (PDF)

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8), p.3299-3308

2010

Volltextzugriff (PDF)

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

The Journal of experimental medicine, 2006-09, Vol.203 (9), p.2201-2213

2006

Volltextzugriff (PDF)

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease

PloS one, 2013-03, Vol.8 (3), p.e60094

2013

Volltextzugriff (PDF)

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

Proceedings of the National Academy of Sciences - PNAS, 2007-10, Vol.104 (40), p.15735-15740

2007

Volltextzugriff (PDF)

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells

Molecular cancer, 2011-06, Vol.10 (1), p.73-73, Article 73

2011

Volltextzugriff (PDF)

Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands

The Journal of immunology (1950), 2009-09, Vol.183 (5), p.3204-3211

2009

Volltextzugriff (PDF)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

PloS one, 2023-06, Vol.18 (6), p.e0286724-e0286724

2023

Volltextzugriff (PDF)

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

American journal of physiology. Renal physiology, 2013-11, Vol.305 (9), p.F1288-F1297

2013

Volltextzugriff (PDF)

Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue

Circulation (New York, N.Y.), 2014-03, Vol.129 (11), p.1244-1253

2014

Volltextzugriff (PDF)

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

ACR open rheumatology, 2020-11, Vol.2 (11), p.662-671

2020

Volltextzugriff (PDF)

Evidence for NK Cell Subsets Based on Chemokine Receptor Expression

Journal of Immunology, 2006-12, Vol.177 (11), p.7833-7840

2006

Volltextzugriff (PDF)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease

The Journal of pharmacology and experimental therapeutics, 2010-10, Vol.335 (1), p.61

2010

Volltextzugriff (PDF)

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

Blood, 2012-08, Vol.120 (7), p.1449-1457

2012

Volltextzugriff (PDF)

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)

PloS one, 2018-03, Vol.13 (3), p.e0192405-e0192405

2018

Volltextzugriff (PDF)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

PloS one, 2019-01, Vol.14 (1), p.e0210593-e0210593

2019

Volltextzugriff (PDF)

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

Metabolism, clinical and experimental, 2013-11, Vol.62 (11), p.1623-1632

2013

Volltextzugriff (PDF)

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice

Arthritis research & therapy, 2014-09, Vol.16 (5), p.445-445, Article 445

2014

Volltextzugriff (PDF)

1 – 25 von 238

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(214)

Publikationsform

Sprache

Englisch
(238)
Japanisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(145)
Humans
(119)
Life Sciences & Biomedicine
(119)
Animals
(74)
Immunology
(52)
Mice
(47)
Biological And Medical Sciences
(45)
Female
(31)
Fundamental And Applied Biological Sciences. Psychology
(30)
Male
(27)
Molecular Sequence Data
(23)
Amino Acid Sequence
(21)
Cells, Cultured
(21)
Cell Line
(20)
Chemokines
(19)
Multidisciplinary Sciences
(19)
Science & Technology - Other Topics
(19)
Biochemistry & Molecular Biology
(18)
Chemokine Ccl4
(17)
Chemokine Ccl5
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Avacopan for the Treatment of ANCA-Associated Vasculitis

CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Cancer associated fibroblast FAK regulates malignant cell metabolism

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Structural basis of ligand interaction with atypical chemokine receptor 3

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells

Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Evidence for NK Cell Subsets Based on Chemokine Receptor Expression

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice

Suchergebnisse filtern